US278923A
(en)
*
|
|
1883-06-05 |
|
Newspapee weappee |
ES2059366T3
(en)
|
1986-03-12 |
1994-11-16 |
American Cyanamid Co |
MACROLID COMPOUNDS.
|
WO1991011457A1
(en)
|
1990-01-24 |
1991-08-08 |
Buckley Douglas I |
Glp-1 analogs useful for diabetes treatment
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
DK39892D0
(en)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
PEPTIDE
|
NZ265452A
(en)
|
1993-03-29 |
1997-09-22 |
Univ Cincinnati |
Analogues of peptide yy, dimers and pharmaceutical compositions
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
US5968899A
(en)
|
1994-06-03 |
1999-10-19 |
Tsumura & Co. |
Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
US5574010A
(en)
|
1994-11-14 |
1996-11-12 |
The Regents Of The University Of California |
Treatment of pancreatic tumors with peptide YY and analogs thereof
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
US5866536A
(en)
|
1995-03-31 |
1999-02-02 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5650386A
(en)
|
1995-03-31 |
1997-07-22 |
Emisphere Technologies, Inc. |
Compositions for oral delivery of active agents
|
SE9600070D0
(en)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
HU227021B1
(en)
|
1996-08-30 |
2010-05-28 |
Novo Nordisk As |
Glp-1 derivatives
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
AU4863797A
(en)
|
1996-11-12 |
1998-06-03 |
Novo Nordisk A/S |
Use of glp-1 peptides
|
CA2271788A1
(en)
|
1996-11-13 |
1998-05-22 |
University Of Cincinnati |
Analogs of peptide yy and uses thereof
|
US5773647A
(en)
|
1997-02-07 |
1998-06-30 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
EP0908515A3
(en)
|
1997-09-16 |
2000-04-26 |
Smithkline Beecham Plc |
Pancreatic polypeptide
|
AU2610799A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
|
AU2610599A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
N-terminally truncated glp-1 derivatives
|
DE69942306D1
(en)
|
1998-02-27 |
2010-06-10 |
Novo Nordisk As |
ABSTRACT OF GLP-1 ANALOG
|
WO1999043707A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
JP2003522099A
(en)
|
1998-02-27 |
2003-07-22 |
ノボ ノルディスク アクティーゼルスカブ |
GLP-1 derivative of GLP-1 having a delayed action profile and exendin
|
US6046167A
(en)
|
1998-03-25 |
2000-04-04 |
University Of Cincinnati |
Peptide YY analogs
|
CA2334298C
(en)
|
1998-06-08 |
2008-01-08 |
Schering Corporation |
Neuropeptide y5 receptor antagonists
|
SE9802080D0
(en)
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and / or irritable bowel syndrome and new use of substances therein
|
EP1100530B1
(en)
|
1998-07-31 |
2003-10-08 |
Novo Nordisk A/S |
In-vitro stimulation of beta cell proliferation
|
MY155270A
(en)
|
1998-09-24 |
2015-09-30 |
Lilly Co Eli |
Use of glp-1 or analogs in treatment of stroke
|
US6903186B1
(en)
|
1998-12-07 |
2005-06-07 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S |
Analogues of GLP-1
|
AU3357800A
(en)
|
1999-02-05 |
2000-08-25 |
Emisphere Technologies, Inc. |
Method of preparing alkylated salicylamides
|
ES2301477T3
(en)
|
1999-02-22 |
2008-07-01 |
Merrion Research I Limited |
SOLID ORAL DOSAGE FORM CONTAINING A POTENTIATOR.
|
AU3240900A
(en)
|
1999-02-22 |
2000-09-04 |
Emisphere Holdings, Inc. |
Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
|
US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
AU775063C
(en)
|
1999-04-30 |
2005-05-12 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
EP1180121B9
(en)
|
1999-05-17 |
2004-09-08 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
GB9923436D0
(en)
|
1999-10-04 |
1999-12-08 |
American Home Prod |
Pharmaceutical compositions
|
US6793934B1
(en)
|
1999-12-08 |
2004-09-21 |
Shire Laboratories, Inc. |
Solid oral dosage form
|
WO2001092206A1
(en)
|
2000-06-02 |
2001-12-06 |
Emisphere Technologies, Inc. |
Method of preparing salicylamides
|
US7049283B2
(en)
|
2000-12-06 |
2006-05-23 |
Novartis Ag |
Pharmaceutical compositions for the oral delivery of pharmacologically active agents
|
JP2004528014A
(en)
|
2000-12-07 |
2004-09-16 |
イーライ・リリー・アンド・カンパニー |
GLP-1 fusion protein
|
WO2002048192A2
(en)
|
2000-12-13 |
2002-06-20 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
JP2004515533A
(en)
|
2000-12-14 |
2004-05-27 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
Peptide YY and peptide YY agonist for treating metabolic disorders
|
US6589938B2
(en)
|
2001-06-29 |
2003-07-08 |
National University Of Singapore |
Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
|
US20030068356A1
(en)
|
2001-07-10 |
2003-04-10 |
Pather S. Indiran |
Sequential drug delivery systems
|
EP1411968B1
(en)
|
2001-07-31 |
2008-09-17 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Glp-1 exendin-4 peptide analogs and uses thereof
|
IL160983A0
(en)
|
2001-09-24 |
2004-08-31 |
Imp College Innovations Ltd |
Use of pyy for preparation of a medicament for modification of feeding behavior
|
JP5196701B2
(en)
|
2001-11-29 |
2013-05-15 |
エミスフィアー テクノロジーズ インコーポレイテッド |
Preparation for oral administration of cromolyn sodium
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
JP2005526020A
(en)
|
2002-02-01 |
2005-09-02 |
ファイザー・プロダクツ・インク |
Dry granulation formulation of azithromycin
|
BR0307727A
(en)
|
2002-02-20 |
2005-01-25 |
Lilly Co Eli |
Fomulation
|
ES2327328T3
(en)
|
2002-07-04 |
2009-10-28 |
Zealand Pharma A/S |
GLP-1 AND PROCEDURES FOR THE TREATMENT OF DIABETES.
|
JP2004131398A
(en)
|
2002-10-08 |
2004-04-30 |
Taihei Chemical Industrial Co Ltd |
Lubricant for tablet
|
US7811989B2
(en)
|
2003-01-17 |
2010-10-12 |
Ipsen Pharma S.A.S. |
Peptide YY analogs
|
WO2004067548A2
(en)
|
2003-01-31 |
2004-08-12 |
Theratechnologies Inc. |
Chemically modified metabolites of regulatory peptides and methods of producing and using same
|
BRPI0407936A
(en)
|
2003-03-19 |
2006-02-21 |
Lilly Co Eli |
pegylated glp-1 compound, method of stimulating the glp-1 receptor in an individual, and use of pegylated glp-1 compound
|
NZ543274A
(en)
|
2003-05-14 |
2007-12-21 |
Emisphere Tech Inc |
Compositions for delivering peptide YY and PYY agonists
|
US7572581B2
(en)
|
2003-06-30 |
2009-08-11 |
Roche Molecular Systems, Inc. |
2′-terminator nucleotide-related methods and systems
|
ES2330638T3
(en)
|
2003-07-11 |
2009-12-14 |
Novartis Ag |
ORGANIC DOSED PHARMACEUTICAL COMPOSITIONS CONTAINING A MICRONIZED SUPPLY AGENT.
|
EP1654004A2
(en)
|
2003-08-08 |
2006-05-10 |
Novo Nordisk A/S |
Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
|
TW200522976A
(en)
|
2003-09-19 |
2005-07-16 |
Novo Nordisk As |
Novel plasma protein affinity tags
|
CA2539253A1
(en)
|
2003-09-19 |
2005-03-31 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
CN101380476A
(en)
|
2003-09-19 |
2009-03-11 |
诺沃挪第克公司 |
Albumin-binding derivatives of therapeutic peptides
|
PT3300721T
(en)
|
2003-11-20 |
2019-06-06 |
Novo Nordisk As |
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
|
RU2006120077A
(en)
|
2003-12-18 |
2008-01-27 |
Ново Нордиск А/С (DK) |
ANALOGUES OF A GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RELATED TO ALBUMIN-LIKE AGENTS
|
ATE461217T1
(en)
|
2003-12-18 |
2010-04-15 |
Novo Nordisk As |
GLP-1 COMPOUNDS
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
CA2555894A1
(en)
|
2004-02-11 |
2005-08-25 |
Amylin Pharmaceuticals, Inc. |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
CN103897066A
(en)
|
2004-02-11 |
2014-07-02 |
安米林药品有限责任公司 |
Hybrid polypeptides with selectable properties
|
JP2007531714A
(en)
|
2004-03-17 |
2007-11-08 |
7ティーエム ファーマ エイ/エス |
Y2 / Y4 selective receptor agonists for therapeutic intervention
|
CN1953763A
(en)
|
2004-03-17 |
2007-04-25 |
7Tm制药联合股份有限公司 |
Y4 selective receptor agonists for therapeutic interventions
|
EA011860B1
(en)
|
2004-03-17 |
2009-06-30 |
7ТиЭм ФАРМА А/С |
Y2 selective receptor agonists for therapeutic interventions
|
EP2060266B1
(en)
|
2004-03-17 |
2011-08-10 |
7TM Pharma A/S |
Y4 selective receptor agonist PP2-36 for therapeutic interventions
|
WO2005099672A1
(en)
|
2004-04-13 |
2005-10-27 |
Ranbaxy Laboratories Limited |
A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
|
BRPI0510226A
(en)
|
2004-05-06 |
2007-10-23 |
Emisphere Tech Inc |
solid pharmaceutical composition, solid dosage form, method for administering heparin to an animal, method for treating or preventing thrombosis in an animal, method for preparing a wet heparin solid dosage form
|
ES2729825T3
(en)
|
2004-05-06 |
2019-11-06 |
Emisphere Tech Inc |
Crystalline polymeric forms of N- [8- (2-hydroxybenzoyl) amino] monosodium caprylate
|
NZ551196A
(en)
|
2004-05-14 |
2010-08-27 |
Emisphere Tech Inc |
Compounds and compositions for delivering active agents
|
GB0412181D0
(en)
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
WO2005121090A1
(en)
|
2004-06-02 |
2005-12-22 |
Abbott Laboratories |
Substituted piperidines that have antiangiogenic activity
|
CN101010339B
(en)
|
2004-07-02 |
2011-11-09 |
布里斯托尔-迈尔斯斯奎布公司 |
Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
MXPA06015049A
(en)
|
2004-07-08 |
2007-02-08 |
Novo Nordisk As |
Polypeptide protracting tags.
|
JP5749879B2
(en)
|
2004-07-12 |
2015-07-15 |
エミスフェアー・テクノロジーズ・インク |
Composition for delivery of peptide YY and peptide YY agonist
|
US7994119B2
(en)
|
2004-07-19 |
2011-08-09 |
University Of Cincinnati |
Compounds for control of appetite
|
US20060078623A1
(en)
|
2004-08-13 |
2006-04-13 |
Emisphere Technologies, Inc. |
Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
|
WO2006049681A2
(en)
|
2004-08-30 |
2006-05-11 |
Bayer Pharmaceuticals Corporation |
Selective neuropeptide y2 receptor agonists
|
US7893017B2
(en)
|
2004-10-07 |
2011-02-22 |
Novo Nordisk A/S |
Protracted GLP-1 compounds
|
JP5107713B2
(en)
|
2004-10-07 |
2012-12-26 |
ノヴォ ノルディスク アー/エス |
Delayed exendin-4 compound
|
US7410949B2
(en)
|
2005-01-18 |
2008-08-12 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
|
JP5175553B2
(en)
|
2005-02-01 |
2013-04-03 |
エミスフェアー・テクノロジーズ・インク |
Gastric retention and controlled release delivery system
|
JP4933455B2
(en)
|
2005-02-02 |
2012-05-16 |
ノヴォ ノルディスク アー/エス |
New insulin derivatives
|
WO2006096515A2
(en)
|
2005-03-04 |
2006-09-14 |
Biorexis Pharmaceutical Corporation |
Modified transferrin fusion proteins
|
GB0504857D0
(en)
|
2005-03-09 |
2005-04-13 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
CN101128214A
(en)
|
2005-03-18 |
2008-02-20 |
诺和诺德公司 |
Extended GLP-1 compounds
|
EP1863537A2
(en)
|
2005-03-18 |
2007-12-12 |
Novo Nordisk A/S |
Dimeric peptide agonists of the glp-1 receptor
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
US20080260818A1
(en)
|
2005-03-28 |
2008-10-23 |
Dexcel Pharma Technologies Ltd. |
Controlled Absorption of Statins in the Intestine
|
AU2006249869A1
(en)
|
2005-05-26 |
2006-11-30 |
Bristol-Myers Squibb Company |
N-terminally modified GLP-1 receptor modulators
|
CA2614619A1
(en)
|
2005-07-11 |
2007-01-18 |
Nastech Pharmaceutical Company Inc. |
Formulations for enhanced mucosal delivery of pyy
|
US8975227B2
(en)
|
2005-07-15 |
2015-03-10 |
Emisphere Technologies, Inc. |
Intraoral dosage forms of glucagon
|
MX2007016024A
(en)
|
2005-07-18 |
2008-03-10 |
Novo Nordisk As |
Peptides for use in the treatment of obesity.
|
EP1971362B1
(en)
|
2005-08-19 |
2014-12-03 |
Amylin Pharmaceuticals, LLC |
Exendin for treating diabetes and reducing body weight
|
US20070049557A1
(en)
|
2005-08-24 |
2007-03-01 |
Hashim Ahmed |
Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
|
JP2009508886A
(en)
|
2005-09-21 |
2009-03-05 |
7ティーエム ファーマ エイ/エス |
Y2-selective receptor agonists for therapeutic intervention
|
EP1934254A1
(en)
|
2005-09-21 |
2008-06-25 |
7TM Pharma A/S |
Y4 selective receptor agonists for therapeutic interventions
|
WO2007061434A2
(en)
|
2005-11-10 |
2007-05-31 |
Nastech Pharmaceutical Company Inc. |
A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
|
US20080255048A1
(en)
|
2005-11-17 |
2008-10-16 |
Moise Azria |
Pharmaceutical Composition
|
WO2007065808A2
(en)
|
2005-12-07 |
2007-06-14 |
F. Hoffmann-La Roche Ag |
Neuropeptide-2 receptor-agonists
|
RU2008124109A
(en)
|
2005-12-08 |
2010-01-20 |
МДРНА, Инк. (US) |
TRANSMISSION DELIVERY OF STABILIZED EXCENDIN COMPOSITIONS
|
WO2007068718A1
(en)
|
2005-12-14 |
2007-06-21 |
Novo Nordisk A/S |
Polypeptide protracting tags
|
US20070197445A1
(en)
|
2006-01-18 |
2007-08-23 |
University Of Cincinnati |
Compounds for control of appetite
|
US20090186817A1
(en)
|
2006-03-21 |
2009-07-23 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of using same
|
EP2007397B1
(en)
|
2006-04-07 |
2013-07-24 |
Merrion Research III Limited |
Solid oral dosage form containing an enhancer
|
WO2007121318A2
(en)
|
2006-04-12 |
2007-10-25 |
Emisphere Technologies, Inc. |
Formulations for delivering insulin
|
CA2649235A1
(en)
|
2006-05-09 |
2007-11-15 |
Frantisek Hubalek |
Insulin derivative
|
EP2040731A4
(en)
|
2006-06-09 |
2010-05-19 |
Merrion Res Iii Ltd |
Solid oral dosage form containing an enhancer
|
CA2656019C
(en)
|
2006-06-28 |
2016-09-13 |
Emisphere Technologies, Inc. |
Gallium nitrate formulations
|
GB0613196D0
(en)
|
2006-07-03 |
2006-08-09 |
Imp Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
ES2296529B1
(en)
|
2006-08-07 |
2009-04-01 |
Laboratorios Farmaceuticos Rovi, S.A. |
PHARMACEUTICAL COMPOSITION WITH ABSORPTION PROMOTERS.
|
US20090318353A1
(en)
|
2006-08-25 |
2009-12-24 |
Novo Nordisk A/S |
Acylated Exendin-4 Compounds
|
ES2498519T3
(en)
|
2006-09-07 |
2014-09-24 |
F. Hoffmann-La Roche Ag |
A procedure for the manufacture of SNAC (SODIUM SALCAPROZATE)
|
TWI430806B
(en)
|
2006-09-13 |
2014-03-21 |
Smithkline Beecham Corp |
Methods for administering long-lasting hypoglycemic agents
|
AR062925A1
(en)
|
2006-09-22 |
2008-12-17 |
Novartis Ag |
METHOD FOR MANUFACTURING TABLETS CONTAINING PHARMACOLOGICALLY ACTIVE AGENTS
|
GB0621973D0
(en)
|
2006-11-03 |
2006-12-13 |
Philogen Spa |
Binding molecules and uses thereof
|
US20100069410A1
(en)
|
2006-12-01 |
2010-03-18 |
Emisphere Technologies Inc. |
acyclovir formulations
|
US20090099074A1
(en)
|
2007-01-10 |
2009-04-16 |
Conjuchem Biotechnologies Inc. |
Modulating food intake
|
US20100022446A1
(en)
|
2007-01-18 |
2010-01-28 |
Novo Nordisk A/S |
Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
|
US20100016237A1
(en)
|
2007-01-18 |
2010-01-21 |
Novo Nordisk A/S |
Novel Peptides for Use in the Treatment of Obesity
|
ES2365648T3
(en)
|
2007-03-02 |
2011-10-07 |
Novartis Ag |
ORAL ADMINISTRATION OF A CALCITONINE.
|
GB0708226D0
(en)
|
2007-04-27 |
2007-06-06 |
7Tm Pharma As |
Y-receptor agonists
|
US8835381B2
(en)
|
2007-06-12 |
2014-09-16 |
Glaxosmithkline Llc |
Methods for detecting protein in plasma
|
CN101970475A
(en)
|
2007-07-09 |
2011-02-09 |
帝国改革有限公司 |
Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
|
US20110183889A1
(en)
|
2007-08-29 |
2011-07-28 |
The Regents Of The University Of California |
Salicylanilide modified peptides for use as oral therapeutics
|
ES2532116T3
(en)
|
2007-09-05 |
2015-03-24 |
Novo Nordisk A/S |
Peptides derived with A-B-C-D and their therapeutic uses
|
WO2009030774A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Truncated glp-1 derivatives and their therapeutical use
|
EP2679597A1
(en)
|
2007-09-05 |
2014-01-01 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
KR20100059864A
(en)
|
2007-09-11 |
2010-06-04 |
몬도바이오테크 래보래토리즈 아게 |
Trap-14 as a therapeutic agent
|
WO2009042922A2
(en)
|
2007-09-27 |
2009-04-02 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of making and using same
|
BRPI0818004B8
(en)
|
2007-10-16 |
2021-05-25 |
Biocon Ltd |
orally administrable solid pharmaceutical composition and the process thereof.
|
US8022048B2
(en)
|
2007-11-02 |
2011-09-20 |
Emisphere Technologies, Inc. |
Method of treating vitamin B12 deficiency
|
US20090124639A1
(en)
|
2007-11-06 |
2009-05-14 |
Emisphere Technologies Inc. |
valacyclovir formulations
|
US20100317057A1
(en)
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
CA2723855A1
(en)
|
2008-05-16 |
2009-11-19 |
Novo Nordisk A/S |
Long-acting y2 and/or y4 receptor agonists
|
CN102123697B
(en)
|
2008-08-18 |
2015-06-10 |
安特拉贝欧有限公司 |
Methods and compositions for oral administration of proteins
|
US8637647B2
(en)
|
2008-09-12 |
2014-01-28 |
Novo Nordisk A/S |
Method of acylating a peptide or protein
|
US8299023B2
(en)
|
2008-09-17 |
2012-10-30 |
Hoffmann-La Roche Inc. |
Neuropeptide-2 receptor (Y-2R) agonists
|
GB0817067D0
(en)
|
2008-09-18 |
2008-10-22 |
7Tm Pharma As |
Intestinal treatment
|
DK2386203T3
(en)
|
2008-10-15 |
2014-02-24 |
Bayer Cropscience Ag |
Use of dithiin-tetracarboximider for the control of phytopathogenic fungi
|
KR20110097807A
(en)
|
2008-11-05 |
2011-08-31 |
에프. 호프만-라 로슈 아게 |
Neuropeptide-2-receptor (y-2r) agonists and uses thereof
|
CN101463081B
(en)
|
2009-01-12 |
2012-07-04 |
华东师范大学 |
GLP-1 derivative
|
EP2395988A2
(en)
|
2009-02-13 |
2011-12-21 |
Boehringer Ingelheim International GmbH |
Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
|
CA2752608A1
(en)
|
2009-02-20 |
2010-08-26 |
Ipsen Pharma S.A.S. |
Cytotoxic conjugates having neuropeptide y receptor binding compound
|
AR077956A1
(en)
|
2009-09-14 |
2011-10-05 |
Bayer Cropscience Ag |
COMBINATIONS OF ACTIVE COMPOUNDS
|
WO2011033068A1
(en)
|
2009-09-18 |
2011-03-24 |
Novo Nordisk A/S |
Long-acting y2 receptor agonists
|
WO2011045232A2
(en)
|
2009-10-13 |
2011-04-21 |
F. Hoffmann-La Roche Ag |
Neuropeptide-2 receptor (y-2r) agonists
|
WO2011058165A1
(en)
|
2009-11-13 |
2011-05-19 |
Novo Nordisk A/S |
Long-acting y2 receptor agonists
|
WO2011084618A2
(en)
|
2009-12-16 |
2011-07-14 |
Nod Pharmaceuticals, Inc. |
Compositions and methods for oral drug delivery
|
ES2625735T3
(en)
|
2009-12-16 |
2017-07-20 |
Novo Nordisk A/S |
GLP-1 analogs and derivatives
|
US20110182985A1
(en)
|
2010-01-28 |
2011-07-28 |
Coughlan David C |
Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
|
WO2011109787A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Methods of administering insulinotropic peptides
|
WO2011116139A2
(en)
|
2010-03-16 |
2011-09-22 |
Chiasma Inc. |
Improved pharmaceutical compositions and methods of delivery
|
EP2560675A1
(en)
|
2010-04-20 |
2013-02-27 |
Novo Nordisk A/S |
Long-acting gastrin derivatives
|
CN102869676A
(en)
|
2010-04-30 |
2013-01-09 |
株式会社三和化学研究所 |
Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability
|
KR101927068B1
(en)
|
2010-05-05 |
2018-12-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
Sequential Combination Therapy by the Weight Reducing Treatment Followed by the DPP-4 Inhibitor
|
DE202010015867U1
(en)
|
2010-11-25 |
2011-05-05 |
Buchhalter, Thomas |
Electromechanical holder for holding navigation and communication devices in the vehicle
|
JP5902194B2
(en)
|
2010-12-16 |
2016-04-13 |
ノヴォ ノルディスク アー/エス |
Solid composition comprising a GLP-1 agonist and a salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid
|
GB201101459D0
(en)
|
2011-01-27 |
2011-03-16 |
Imp Innovations Ltd |
Novel compounds and thier effects on fedding behaviour
|
ES2612278T3
(en)
|
2011-04-12 |
2017-05-16 |
Novo Nordisk A/S |
GLP-1 double-acylated derivatives
|
JP6006309B2
(en)
|
2011-07-08 |
2016-10-12 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals,Llc |
Engineered polypeptides with increased duration of action and reduced immunogenicity
|
DE102012102301B4
(en)
|
2012-03-19 |
2021-06-17 |
OSRAM Opto Semiconductors Gesellschaft mit beschränkter Haftung |
Optoelectronic semiconductor chip and headlight with such a semiconductor chip
|
PT2827845T
(en)
|
2012-03-22 |
2019-03-29 |
Novo Nordisk As |
Compositions comprising a delivery agent and preparation thereof
|
ES2952874T3
(en)
|
2012-03-22 |
2023-11-06 |
Novo Nordisk As |
GLP-1 peptide compositions and preparation thereof
|
JP6356660B2
(en)
*
|
2012-03-22 |
2018-07-11 |
ノヴォ ノルディスク アー/エス |
Compositions containing delivery agents and their preparation
|
US20150141336A1
(en)
|
2012-05-29 |
2015-05-21 |
Novo Nordisk A/S |
Pancreatic Peptide Compounds and Use
|
JP6517690B2
(en)
*
|
2012-06-20 |
2019-05-22 |
ノヴォ ノルディスク アー/エス |
Tablet formulation containing peptide and delivery agent
|
CA2877056A1
(en)
|
2012-07-01 |
2014-01-09 |
Novo Nordisk A/S |
Use of long-acting glp-1 peptides
|
MY172578A
(en)
|
2013-05-02 |
2019-12-03 |
Novo Nordisk As |
Oral dosing of glp-1 compounds
|
TW201534616A
(en)
|
2013-05-02 |
2015-09-16 |
Glaxosmithkline Ip Dev Ltd |
Therapeutic peptides
|
JP6629198B2
(en)
|
2013-11-15 |
2020-01-15 |
ノヴォ ノルディスク アー/エス |
HPYY (1-36) having a β-homoarginine substitution at position 35
|
MX369818B
(en)
|
2013-11-15 |
2019-11-22 |
Novo Nordisk As |
Selective pyy compounds and uses thereof.
|
WO2015155151A1
(en)
|
2014-04-07 |
2015-10-15 |
Novo Nordisk A/S |
Double-acylated glp-1 compounds
|
WO2016120380A1
(en)
*
|
2015-01-29 |
2016-08-04 |
Novo Nordisk A/S |
Pharmaceutical composition for oral glp-1 administration comprising a tablet core and immediate release coating
|
IL292417A
(en)
|
2015-02-09 |
2022-06-01 |
Entera Bio Ltd |
Treatment of osteoporosis
|
AR104984A1
(en)
|
2015-06-12 |
2017-08-30 |
Novo Nordisk As |
SELECTIVE COMPOUNDS FOR PYY AND ITS USES
|
AU2016335287A1
(en)
*
|
2015-10-07 |
2018-04-12 |
Cyprumed Gmbh |
Pharmaceutical formulations for the oral delivery of peptide drugs
|
TWI797133B
(en)
|
2017-06-09 |
2023-04-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Solid compositions for oral administration
|
WO2019038412A1
(en)
|
2017-08-24 |
2019-02-28 |
Novo Nordisk A/S |
Glp-1 compositions and uses thereof
|
JP6898518B2
(en)
|
2018-02-02 |
2021-07-07 |
ノヴォ ノルディスク アー/エス |
A solid composition comprising a GLP-1 agonist, a salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid and a lubricant.
|
MX2022000827A
(en)
*
|
2019-08-07 |
2022-02-16 |
Novo Nordisk As |
Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid.
|